Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.30
    OpenPayerBilling CodesDiseases and Disorders of the Kidney and Urinary TractDRG 653-major-bladder-procedures-with-mcc
    Ask Trek AI about this page

    Major Bladder Procedures with MCC: Inpatient Reimbursement Overview

    DRG 653 encompasses major bladder procedures with a Major Complication or Comorbidity, such as complex resections or urinary reconstruction accompanied by significant comorbid conditions. Understanding this Diagnosis-Related Group is important for inpatient reimbursement because the classification directly affects Medicare payment levels based on case complexity and resource use.

    Customize your policy alerts

    Sign up for drg 653 policy alerts

    Get alerted when payer policies referencing 653 are released or updated.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    DRG 653 Overview

    DRG 653 covers major bladder procedures performed for complex bladder disease, typically including extensive resections, urinary diversion, or reconstruction when a Major Complication or Comorbidity is present. This Diagnosis-Related Group groups cases with higher resource intensity driven by operative complexity, prolonged hospitalization, and increased need for postoperative care. It matters for Medicare payment because cases classified to this Diagnosis-Related Group receive higher inpatient reimbursement relative to less complex bladder procedure groups, reflecting the greater expected costs of treatment and recovery.

    Table of contents

    Progress1 / 3

    Explore openpayer tools

    • Billing CodesCPT, HCPCS, DRG & more
    • Reimbursement RatesCommercial vs. Medicare rate reports
    • Facility ComparisonBeds, revenue & payer mix
    • ProvidersHospitals & facilities
    • PayersPlans & market footprint
    • Taxonomy CodesNUCC specialty codes
    • ModifiersCPT modifiers & usage
    • Prior AuthorizationPA policies by payer & drug
    • Timely FilingFiling deadlines by payer
    • Coverage CriteriaMedical necessity by payer
    • Payer ContactsClaims, PA & appeals contacts
    View all tools

    Clinical Trials

    • Perioperative optimization and complication-reduction trials: randomized or pragmatic studies testing preoperative assessment pathways, enhanced recovery after surgery (ERAS) protocols, and perioperative interventions (e.g., fluid management strategies, infection prophylaxis bundles, or blood conservation techniques) for patients undergoing major bladder procedures with significant comorbidity. These trials focus on older, high-acuity inpatients who often have malignant or complex benign bladder pathology and multiple organ dysfunctions, aiming to reduce rates of perioperative complications, intensive care utilization, and prolonged length of stay. Results are directly relevant to providers and payers because successful protocols can lower complication-related costs, readmissions, and resource use for this high-cost DRG.
    • Comparative effectiveness studies of surgical approaches and reconstructive techniques: observational cohort studies or randomized trials comparing open cystectomy versus minimally invasive approaches (laparoscopic/robotic) and different urinary diversion or reconstruction methods in patients requiring major bladder surgery. These studies enroll patients across cancer stages and functional statuses to evaluate outcomes such as perioperative morbidity, oncologic control, functional results (continence, renal function), and long-term healthcare utilization. For clinicians and payers, evidence on which operative strategies produce better clinical outcomes and lower downstream costs informs surgical decision-making, case selection, and bundling/payment policies for this DRG.
    • Post-discharge outcomes and survivorship/quality-of-life research: longitudinal studies and registry-based analyses assessing post-acute needs, complication trajectories, home health utilization, and patient-reported outcomes (physical function, stoma/urostomy care, psychosocial adaptation) after discharge from major bladder procedures with major complications. These studies target the transition-to-home phase, including patients with MCC who have high rates of readmission, durable medical equipment needs, and caregiver burden, and they test interventions like structured discharge planning or remote monitoring. Findings help payers and health systems design post-discharge programs, targeted case management, and value-based reimbursement strategies to reduce readmissions and improve long-term outcomes for this resource-intensive DRG.

    Related Codes

    650-KIDNEY-TRANSPLANT-WITH-HEMODIALYSIS-WITH-MCC

    Kidney Transplant with Hemodialysis with Major Complication or Comorbidity: Inpatient Reimbursement Overview

    651-KIDNEY-TRANSPLANT-WITH-HEMODIALYSIS-WITHOUT-MCC

    Kidney Transplant with Hemodialysis without MCC: Inpatient Reimbursement Overview

    652-KIDNEY-TRANSPLANT

    Kidney Transplant: Inpatient Reimbursement Overview

    654-MAJOR-BLADDER-PROCEDURES-WITH-CC

    Major Bladder Procedures with CC: Inpatient Reimbursement Overview

    655-MAJOR-BLADDER-PROCEDURES-WITHOUT-CC-MCC

    Major Bladder Procedures without CC/MCC: Inpatient Reimbursement Overview

    656-KIDNEY-AND-URETER-PROCEDURES-FOR-NEOPLASM-WITH-MCC

    Kidney and Ureter Procedures for Neoplasm with MCC: Inpatient Reimbursement Overview

    657-KIDNEY-AND-URETER-PROCEDURES-FOR-NEOPLASM-WITH-CC

    Kidney and Ureter Procedures for Neoplasm with CC: Inpatient Reimbursement Overview

    658-KIDNEY-AND-URETER-PROCEDURES-FOR-NEOPLASM-WITHOUT-CC-MCC

    Kidney and Ureter Procedures for Neoplasm without CC/MCC: Inpatient Reimbursement Overview

    659-KIDNEY-AND-URETER-PROCEDURES-FOR-NON-NEOPLASM-WITH-MCC

    Kidney and Ureter Procedures for Non-Neoplasm with MCC: Inpatient Reimbursement Overview

    660-KIDNEY-AND-URETER-PROCEDURES-FOR-NON-NEOPLASM-WITH-CC

    Kidney and Ureter Procedures for Non-Neoplasm with CC: Inpatient Reimbursement Overview

    Showing 1–10 of 41

    References

    1. 1.CPT® Codes and Descriptions. AAPC. Retrieved Aug 11, 2026.Maintains the CPT code set's official descriptions and guidelines, licensed from the American Medical Association, used as the definitional source for CPT codes on this page.
    2. 2.HCPCS Quarterly Update. Centers for Medicare & Medicaid Services (CMS). Retrieved Aug 11, 2026.CMS's quarterly release of HCPCS Level II codes and short/long descriptors, the source for HCPCS code definitions and update history.
    3. 3.ICD-10-CM Full Code List. Centers for Medicare & Medicaid Services (CMS). Retrieved Aug 11, 2026.CMS's complete ICD-10-CM diagnosis code list, used to cross-reference diagnosis codes associated with this procedure or service.
    Published by

    Trek Health powers OpenPayer with a leading commercial payer intelligence platform, seamlessly converting fragmented payer data into actionable insights for provider organizations.

    Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.